Embed Size (px)
Citation preview
Discover. Develop.Get to market.
9-11 November 2015Congress Centre, Basel, Switzerland
11th Annual
Co-located with
Created by
Part of
Partnered with
Supported by
terrapinn.com/EAC2015
EXCELLENT NEW RESEARCH IN THE AREA OF ANTIBODY ENGINEERING. VERY INNOVATIVE. EXCELLENT LIST OF SPEAKERS. BEAUTIFULLY ORGANIZED MEETING.”
“
CSO BIOMUNEX PHARMACEUTICALS
Inva
luab
le Net
workin
g
Two D
rinks
Rec
eptio
ns, o
ff-sit
e and
on-si
te pa
rties,
even
ing P
oster
Pres
entat
ion S
essio
n alon
gside
exten
ded b
reaks
and l
unch
es w
ill ens
ure pl
enty
of
time t
o mee
t with
othe
r atte
ndee
s.
Your Congress, Your Way
Challenges affecting the whole sector will be addressed in high-level plenary sessions,
branching off into targeted sessions, suited to your specific interests.
Immunotherapy and Immune Checkpoint Antibodies, Antibody-Drug Conjugate (ADC) Development,
Bispecifics & Novel Constructs, Early Discovery & Analytics, Preclinical Development, CMC/Developability, Manufacture & Purification,
Clinical Development & Trials, Novel Applications for Antibodies and Platform
Technology Showcase.
Bigger & Better
3 days packed full of content. Covering:
Cancer and Immunotherapy, ADCs, preclinical and clinical
development, manufacturing, analytics, target discovery,
regulation and novel applications.
Solution Provider Exhibition
Where buyers meet suppliers offering innovative
services and technologies.
New a
nd impro
ved
for 2
015
Focu
sed
sess
ions o
n immun
e che
ckpo
int
antib
odies
and
emerg
ing im
munot
herap
ies.
Lead
ing on
colog
y clin
ician
s disc
uss h
ow to
get n
ew
therap
eutic
s into
the c
linic.
Targ
et dis
cove
ry an
d co
mputat
ional
biolog
y stra
tegies
for ea
rly p
hase
pro
tein e
ngine
ering
and
new
antib
ody f
ormats
.
Poster
pres
entat
ion se
ssion
.
WHATS IN STORE FOR 2015
Save money and book early @ terrapinn.com/EAC2015
The European Antibody Congress is where pharma, biotechs, clinicians, researchers & innovative start-ups gather to develop new strategies and partnerships to advance antibody drug discovery, development, and commercialisation. Join the largest antibody event focused on getting important new therapeutics and immunotherapies into the clinic and see where antibody development is headed next.
1
2
3
4
5
6
7
8
9
10
REASONS TO ATTEND
Engage with 60+ high-level pharma and biotech including Seattle Genetics, Novartis, Roche, Pfizer, Memorial Sloan Kettering, Medimmune, NBE Therapeutics, Genentech, Merrimack, Oxford Biotherapeutics, Philogen, Janssen, and Cancer Research UK.
Hear how industry leaders like Genentech, Philogen, NBE therapeutics & Oxford Biotherapeutics envision the future of ADCs as they explore developmental updates and new emerging technologies.
Benefit from numerous networking opportunities that bring together all congress attendees with Two Drinks Receptions, offsite and onsite parties, an Evening Poster Presentation Session alongside extended breaks and lunches.
Network with 400 international, antibody stakeholders over 3 days. Meet and do business with representatives from big pharma, biotech, investors, clinicians and researchers.
Meet like-minded industry experts specific to antibody therapeutic areas and antibody development stages in the targeted conference sessions.
Examine how to reduce costs of purification and manufacture and explore best practices in CMC and developability from KBI, BTI A*, Synthon, Pall and Fujifilm Diosynth.
Get updated on the latest bispecifics, complex molecules and scaffolds by Medimmune, Roche, Abbvie and Janssen.
Top oncology clinicians such as Michael Postow and not for profit groups Cancer Research UK will help to understand the clinical development process, covering key issues in clinical practice and partnering.
Explore the newest methods of discovery, target identification, analytics and computational biology with 4-Antibody, Pfizer and Baker Lab Washington.
Learn from success stories in immunotherapy and immune checkpoint antibodies from Novartis, Pfizer and Memorial Sloan Kettering.
10
Save money and book early @ terrapinn.com/EAC2015
HIGH SCIENTIFIC VALUE OF THE TALKS, KNOWLEDGEABLE SPEAKERS, GREAT NETWORKING WITH EUROPEAN ENTITIES, ESPECIALLY FOR US BASED COMPANIES”
“
VP AMBRX INC.
CO-LOCATED WITH
More information is available at terrapinn.com/HPAPI2015
More information is available at terrapinn.com/biosimilars2015
COST-EFFECTIVE BIOLOGICS FOR PAYERS, PRESCRIBERS AND PATIENTS
• Pharmacovigilance in biosimilars• Pure-play perspective: Why the ‘wait-and-see approach’ is the best strategy for the small
cap companies• 360° perspective panels consisting of industry panellists, physicians, pharmacists, patient
advocacy groups, payers, regulators and health authorities• Considering the innovator when developing the biosimilar• With its first approved biosimilar, what effect is the UShaving on the global regulatory
environment for biosimilars?• How to implement regulatory guidelines into your product development strategy• Navigating the world of patents and IP to get your biosimilar to market• Naming conventions for biosimilars and subsequent labelling practices• How quickly will biosimilars be adopted in clinical practice?• Budget impact analysis of future healthcare uptake of biosimilars
COST-EFFECTIVE BIOLOGICS FOR PAYERS, PRESCRIBERS AND PATIENTS
• Containment strategies and chemical exposure control methods• Setting the scene for high potency innovation: The hazard versus the risk• Beyond the isolator: Considerations for full room filtration and containment• Outsourcing - Why? When?• How to ensure facilities and equipment are fit for purpose and avoid overdesigning• How to choose between new equipment and enhanced existing solutions for your high potency
API manufacturing needs• How best to manage legacy facilities when repurposing for high potency API manufacturing• Will continuous processing ever be a reality for high potency API manufacturing?• Enabling standardisation and cleaning validation for high potency API manufacturing processes• How to ensure your external partners are using the best equipment and methods for your projects
SPOTLIGHT ON SPEAKERS
Dr Peter Senter, Vice President of Chemistry, Seattle GeneticsDr Peter Senter has served as Vice President, Chemistry since September 2002 and in February 2009, Dr. Senter was recognized as the company’s first Distinguished Fellow. He leads Seattle Genetics’ chemistry department, which carries out research in antibody-drug conjugate technologies, including the development of potent drug payloads, novel linker systems, conjugation methodology and mechanism of action studies. He is the Senior Editor of Molecular Cancer and serves as an Affiliate Professor of Bioengineering at the University of Washington.
Dr Senter will give an exciting keynote session on the status of the ADC field and what might be in store for the future including an overview of the technologies that have been most pivotal in the development of approved ADCs, from clinical advancement to what partnerships and collaborative efforts have been formed to create success in ADC development.
Dr Emma Lees, Vice President, Oncology Biotherapeutics, Novartis Institute for Biomedical Research (NIBR)Dr Emma Lees has over 25 years of experience in the field of oncology research and more than 16 years of industry experience in therapeutic drug discovery and organizational leadership. Dr. Lees is the Vice President of Oncology and Site Head for Emeryville at Novartis Institutes for Biomedical Research (NIBR). Her responsibilities include leading internal, world-class research to identify novel oncology drug targets, development of appropriate assays for therapeutic discovery, management of project progression through preclinical research, and interface with the preclinical and clinical development. She serves as part of the global oncology leadership team, building the strategy and implementation of the Oncology portfolio for Novartis, and has global responsibility for the oversight to the oncology biologics pipeline.
Dr Lees will be discussing precision oncology and how to best use genomics to correctly identify drug targets and optimize the preclinical development of therapeutics.
Dr Hans-Peter Gerber, Vice President, Pfizer Worldwide Research & Development, PfizerDr Hans-Peter Gerber is leading the Bioconjugate Discovery and Development group at the Oncology Research Unit in Pearl River, NY, where he is building a program to develop novel biotherapeutic drugs, including antibody drug conjugates and bi-specific compounds redirecting immune effector cells to the tumor environment. In 1995 he joined Genentech as a visiting scientist, where he spent 11 years in research studying the mechanisms involved in the regulating blood vessel formation and developing therapeutic antibodies interfering with tumor growth. In March 2006, he joined Seattle Genetics as head of the Translational Biology Department, where he contributed to the development of therapeutic antibodies and ADCs.
Dr Gerber will present on how to best select targets, payloads and reduce off-target toxicity in alternative modalities (ADC or Bispecific) when developing a new therapeutic platform, in this case redirected T-Cell targeting, for the first time.
Dr Michael Postow, Medical Oncology Fellow Medicine, Memorial Sloan KetteringDr Michael Postow is a physician on the faculty at Memorial Sloan Kettering Cancer Center in the Melanoma and Immunotherapeutics Oncology Service. He completed medical school at New York University School of Medicine and internal medicine residency training at Brigham and Women’s Hospital/Harvard Medical School. He then returned to New York City to pursue a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center where he conducted research with Dr. Jedd Wolchok in melanoma and immunotherapy. He has participated in a number of clinical trials involving immunotherapeutic agents, most notably leading a phase II study of the combination of nivolumab and ipilimumab and organizing a trial combining radiotherapy and immunotherapy. The lead author in an exciting new study on combining immunotherapy drugs ipilimumab (Yervoy™) and nivolumab (Opdivo™).
He will be covering the various clinical aspects involved in the development of immune checkpoint modulators and whether antibody combinations are preferable.
Dr Christian Klein, Head of Oncology Programs, RocheDr Christian Klein, Distinguished Scientist is Head of Oncology Programs at the Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Switzerland specialized in the discovery, validation and preclinical development of antibody based cancer immunotherapies and bispecific antibodies. During his >14 years at Roche he has made major contributions as research project leader to the development and FDA/EMA approval of obinutuzumab, the preclinical development of four bispecific antibodies currently in active clinical development: 1) CEA-IL2v immunocytokine RG7813 (Ph I), 2) anti-Ang-2/VEGF CrossMAb RG7221 in oncology (Ph II), 3) anti-VEGF/Ang-2 CrossMAb RG7716 in ophthalmology (Ph I) and 4) CEA-CD3 T cell bispecific antibody RG7802 (Ph I), as well as the development of Roche’s novel proprietary bispecific antibody platforms e.g. the CrossMAb technology. He’ll be exploring engineering, design and preclinical development of novel formats, particularly the challenges and benefits of T-Cell Bispecific antibodies.
SPOTLIGHT ON SPEAKERS
Dr Ulf Grawunder, CEO, NBE TherapeuticsDr Ulf Grawunder is founder and CEO of NBE-Therapeutics, a Swiss Biotech company incorporated in 2012, which focuses on the development of “next-generation” antibody-drug conjugates for cancer therapy. Prior to that, Ulf co-founded 4-Antibody in 2004, a Swiss therapeutic antibody engineering company, where he initially served as CEO and later as CSO, until the company was sold to US-based Agenus in 2013.
Ulf is member of a number of national and international boards of for profit and non-profit organizations, including the scientific advisory board of the Bavarian Immunotherapies Network, BayImmuNet, Germany and the Board of the Swiss Biotech Association. Dr Grawunder will be discussing new methods of ADC development to improve efficacy and decrease tumor resistance.
Dr Keith Wilson, CSO, Oxford BiotherapeuticsDr Keith Wilson has over 20 years’ experience of life sciences research and development, specializing in oncology and immunology. He joined Oxford BioTherapeutics from Abbvie where he was Global Leader, Antibody Drug Conjugates and Director, Biologics Technology, and was responsible for corporate ADC strategy with multiple programs in pre-clinical and clinical development, as well as leading a large multi-functional discovery team. Oxford BioTherapeutics is a clinical stage biotechnology company that is developing a range of innovative antibody based therapeutics, including antibody-drug conjugates (ADCs), for the treatment of cancer. Dr Wilson will be discussing precision cancer therapy ADCs with novel antibody and cancer toxin technologies, target discovery for optimal ADC activity, using partnership and collaborations to advance ADC development into the clinic and improving efficacy of ADCs by identifiying antigen targets from a wide range of cancer types.
Prof Dr Dario Neri, Professor, Department of Chemistry & Applied Biosciences, ETH Zurich; Founder, PhilogenThe research of the group of Dr Neri focuses on the engineering of therapeutic antibodies for the therapy of cancer and other angiogenesis-related disorders. Other research activities include the chemical proteomic discovery of novel vascular markers of pathology and the development of DNA-encoded chemical libraries. Dario Neri is a co-founder of Philogen, a Swiss-Italian biotech company which has brought five antibody-based products into multicenter clinical trials for the therapy of cancer and of rheumatoid arthritis.Dr Neri will be giving an update on armed antibodies for the treatment of cancer and of chronic inflammation focusing on transferring therapeutics from the bench to the clinic.
Prof Thomas Powles, Clinical Professor of Genitourinary Oncology, Barts Cancer InstituteProf Powles is the lead for solid tumor research at Barts Cancer Institute and also leads the genitourinary cancer group at BCI. His work focuses on a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies. They exploit functional imaging and tissue collection. Alongside these trials, his research focuses on correlation of novel biomarkers and aims to define markers that are of prognostic value and can predict response or resistance to therapy. His group recently published research in Nature on a breakthrough Anti-PD-L1 immunotherapy treatment in the treatment of metastatic bladder cancer. Prof Powles will be looking at what we can learn from his recent study when sending novel formats into the clinic, as well as how to respond with new safety and efficacy guidelines of immunotherapies and how to use new immunotherapy alongside other modalities to improve patient outcomes.
Dr Volker Schellenberger, President & CEO, AmunixVolker Schellenberger is a co-founder of Amunix and currently serves as President and CEO. Dr. Schellenberger has extensive industry experience in protein engineering and drug discovery. Previously, he headed the Protein Engineering department at Genencor, where he invented combinatorial consensus mutagenesis, selection by micro-compartmentalization, as well as mutator technology. In addition, he initiated and led collaborations with Seattle Genetics that focused on antibody-enzyme fusion proteins. Prior to his work on biotherapeutics, Dr. Schellenberger directed projects optimizing enzymes for industrial applications as well as microbes for metabolic pathway engineering. Dr. Schellenberger is the author of over 40 scientific papers and an inventor on more than 70 issued and pending patent applications. He is also the recipient of the Karl Lohman award of the German Society of Biochemists.
BIG TOPICS
IMMUNE CHECKPOINT ANTIBODIES AND IMMUNOTHERAPY
Immunotherapy drugs are considered to be more efficient than the traditional options, and they are set to be used for the treatment of a variety (around 60%) of cancer types during the next ten years. Using T-Cells to reengage the body’s immune system has been more and more widely reported and is set to revolutionise the way cancer is treated. A focused session looking at developing immune checkpoint antibodies as well as how to get T-Cell therapies from bench to bedside and more will take place this year. We will look at developing novel immunotherapies and how they behave in the clinic with case studies from Novartis, Roche and Memorial Sloan Kettering Hospital as well as a very special presentation from Pfizer discussing their new immunotherapy for the first time.
This year’s conference will cover:
BISPECIFIC ANTIBODIES
Focusing on the next generation of cancer application and autoimmune disease therapies. We will look at the mechanism of action of bispecifics in humans, new technologies, novel constructs and engineering bispecifics while considering later stages of clinical application.
ADCs
The major challenges of developing ADCs from tackling the bottleneck from bench to bedside will be addressed. Looking at novel payloads, decreasing side effects, target identification and preclinical development. An overview of the field will be given by Peter Senter from Seattle Genetics and followed by informative case studies from NBE Therapeutics, Oxford Biotherapeutics and other leading minds in the field from both pharma and biotech.
THE FUTURE From huge advances in cancer therapies and immune system modulation to recent developments in treating infectious disease, inflammation, T-Cell biology, neurological applications, and creating vaccines: antibody based drugs are set to have profound effects in every area of medicine in the very near future. We will be looking to the future of new targets, constructs and applications in 2016. Janice Reichardt will give a closing keynote on antibodies to watch for 2016.
DISCOVERY AND DEVELOPMENT
New methods and technologies will be explored, such as advances in computational biology, analytics, and target discovery. Mass spectrometry, molecular assessment, structural analysis, stability and scalability will all be discussed. We will explore what the most important factors are in developing antibodies of every format from mAbs to ADCs with a view to clinical success and commercialisation.
PLATFORM TECHNOLOGY SHOWCASE
A new targeted session exploring the most innovative new platform technologies being developed towards antibody engineering and development will take place.
CMC, MANUFACTURE & PURIFICATION
Addressing the challenges of developing a molecule which is stable producible and has a high yield. Experts will discuss developing biologics from start to finish, ensuring GMP and quality at a commercial scale, new animal models, and stability. Manufacture and purification of ADCs, continuous manufacture of antibodies as well as new cost effective methods of antibody purification will also be covered.
CLINICAL DEVELOPMENT
How to ensure clinical viability of antibody drugs will be the focus of this session with case studies from the leading researchers, clinical oncologists and thought leaders. Topics such as ensuring clinical development through innovative partnering, considering immunogenicity, and decreasing costs in trials will be discussed.
08:00
11:40
10:40
09:00
09:05
09:25
09:50
10:15
Registration opens
Networking refreshment break
Opening Keynotes: New antibody formats and targets
Roundtable Discussion Session
16 senior level tables hosted by thought leaders on key challenges and opportunities antibody drug development. Participants are invited to join in the small-group discussions on a topic of primary importance to them. See Page 13 for details
The past, present, and future of antibody-drug conjugates• The overall status of the field and future expectations• An overview of technologies that led to the currently approved ADCs and new technologies under investigation for future ADCs • Clinical advancements • What partnerships and collaborative efforts have been formed to create success in ADC development?Dr Peter Senter, Vice President Chemistry, Seattle Genetics
Precision oncology: Treating cancer using targeted therapies that pinpoint genetic mutations • Identifying pathways most commonly associated with cancer• Screening compounds to identify ones with greatest potential to impact pathway• Identifying biomarkers and create diagnostic tools• Targeting patients most likely to benefit from therapyDr Emma Lees, Vice President, Oncology Biotherapeutics at Novartis, Novartis Institutes for BioMedical Research (NIBR)
Matching target biology with the optimal therapeutic modality in oncology• From antibody drug conjugates to bispecific, redirected T-cell targeting• Payload selection, target biology and reduction in off-target toxicity of ADCs• Progress made with bispecific, redirected T-cell targeting programmesDr Hans-Peter Gerber, Vice President, Pfizer Worldwide Research & Development
Reserved for Platinum Partner
Chair’s opening remarksDr Alain Beck, Senior Director CIPF, Associate Editors, mAbs
DAY 1 – MONDAY 9 NOVEMBER, 2015
Analytics for ADCs
Alain Beck, Senior Director, Antibody Physico-Chemistry, CIPF; Associate Editor,
mAbs
A needle in a haystack. Shortcuts to visualising and validating
biomarkers for disease diagnosis and therapy
Jeremy Clarke & Richard Willock, Asterand Bioscience
Non-radioactive potency assays for ADCs
Dr Alexis Rossignol, R&D Project Manager, Clean Cells
Using human tissue-based research solutions for antibody drug discovery
How to use bioinformatics programmes for target discovery
CMC and developability considerations
Dr Prathima Acharya, KBI Biopharma
Designing ADCs
Dr George Badescu, Scientific Director – Conjugation & Protein Engineering, Abzena
The next generation of antibody conjugates: moving beyond cytotoxic payloads
Dr David Rabuka, Head of Global R&D, Chemical Biology, Catalent
Tackling the challenges of Target Discovery
Optimising GMP at a commercial scale Optimising drug deliveryPartnering and licensing: How to get your
antibody to market quickly and cost-effectively
12:45
15:30
14:15
14:35
14:55
15:15
Networking lunch
Networking refreshment break
ADCs
Tackling the bottleneck: From bench to bedside
Novel enzymatic conjugation for developing next-generation antibody drug conjugates• Sortase enzymes provide a robust and efficient means
to attach toxic payloads to antibodies• Highly site-specific conjugation yields homogenous
drug product with defined efficacy, PK properties and safety profile.
• Production of dual payload ADCs may help address resistance and provide opportunity to tackle tumor heterogeneity and quiescence
Dr Ulf Grawunder, CEO, NBE Therapeutics
Selecting payloads for antibody drug conjugates• Choice of payloads to overcome resistance
mechanisms• Identification and evaluation of novel ADC payloads • Creating next generation ADCs, making use of
additional payloads with the potential to address current shortcomings
Dr Vishal Verma, Scientist, Medicinal Chemistry, Genentech
Optimized Site Specific ADC Generation • Enabling precise, and programmable, site-specific
chemical protein modification• The development of novel conjugation chemistry resulting
in ADCs with enhanced stability • Linker chemistry that optimizes the potency of the
cytotoxic payloadDr David Rabuka, Head of Global R&D, Chemical Biology, Catalent
Innovation in cancer
Precision cancer therapy ADCs with novel antibody and cancer toxin technologies• Oncology target discovery for optimal ADC activity • Using partnership and collaborations to advance ADC
development into the clinic• Improving efficacy of ADCs by providing a unique
range of validated, novel antigen targets identified from a wide range of cancer types
Dr Keith Wilson, CSO, Oxford Biotherapeutics
Immune checkpoint antibodies & bispecifics
Immune checkpoint antibodies and immunotherapy
Clinical development of immune checkpoint modulators• Is combination of antibodies necessary?• How do we best sequence these antibodies?• How do we image patients for the effects?• How can we best assess side effects?Dr Michael Postow, Medical Oncology Fellow Medicine, Memorial Sloan Kettering
Anti-PD-L1 immunotherapy treatment in the treatment of metastatic bladder cancer• What can we learn from this when sending novel
formats into the clinic?• How do we respond to new safety and efficacy
guidelines of new immunotherapies?• How can we use new immunotherapy alongside other
modalities to improve patient outcomes?Prof Thomas Powles, Clinical Professor of Genitourinary Oncology, Barts Cancer Institute
CTL cell therapy in cancer: Driving toward the clinic• Complete and durable clinical responses to leukaemias
through (CAR) T Cells • Safety considerations when adopting novel formats
into the clinicDr Alfonso Quintas, Global Clinical Leader, Oncology, Novartis
Immune checkpoint technologiesReserved for supporting partner
DAY 1 – MONDAY 9 NOVEMBER, 2015
16:15 XTEN Drug Linkers with Precisely Controlled Chemical Structures for High Drug Loads and Optimized Tissue Uptake• Size-optimized polymer linkers • Enhanced tumor uptake triggered by extracellular
proteolysis followed by intracellular drug release• Solubilization of hydrophobic payloadsDr Volker Schellenberger, President & CEO, Amunix
Bispecifics
A novel T-cell bispecific antibody platform• Introduction of a novel IgG-based T-cell bispecific
(TCB) antibody platform enabled by the CrossMAb technology
• Engineering, design and advantages as compared to existing T-cell bispecifics platforms
• Preclinical properties of the CEA-CD3 TCB (RG7802) currently in Phase 1 clinical trials
Dr Christian Klein, Head Oncology Programs, Roche
16:55
16:55
17:35
16:35 The future of ADCs
Developing ADCs for non-oncological applications • Using ADCs to treat inflammatory disease• The targeted delivery of small molecule modulators for
indications beyond oncology• Developing new ADC carriers Dr Feng Wang, Principal Investigator, Calibr - California Institute for Biomedical Research
Decreasing side effects in ADCs• Maintaining stability and increasing circulation time• What are the most important safety considerations
when developing ADCs?• How can we improve preclinical development steps to
make them safer once they enter the clinic?Dr Florence L’Hospice, Director, Pharmaceutical Operations, Innate Pharma
Advances in ADC design for cancer treatment• Have ADCs fulfilled the promise of patient benefit?• Current developments in ADCs utilising ImmunoGen’s
maytansinoid platform• What’s next in designing effective, well-tolerated
ADCs?John Lambert, CSO & Executive VP, ImmunoGen
Armed antibodies for the treatment of cancer and of chronic inflammation: From the bench to the clinic• Comparative evaluation of different types of armed
antibodies• Quantitative evaluation of targeting• Emerging clinical resultsProf Dr Dario Neri, Professor, Department of Chemistry & Applied Biosciences, ETH Zurich; Founder, Philogen
Engineering bispecifics and novel formats
Improving target cell specificity using a novel monovalent bispecific IgG design• What are the main challenges in increasing accuracy of
bispecifics?• What are the most important steps that need to be
taken during design?• How can this novel method improve preclinical and
clinical success of bispecific drugs?Dr Partha Chowdry, Principal Scientist, Medimmune
Tumour antigen-binding bispecific antibodies for cancer treatment• New applications for bispecifics in experimental cancer
therapy• Molecules that bind different cell surface proteins to
achieve more complete blockage pathways• Application of bispecifics in the clinic, what method
works best to accelerate this process? Dr Ulrich Brinkmann, Expert Scientist, Roche Pharma Research & Early Development, Roche Innovation Center Penzberg, FRG
Evaluating clinical data to discover how DvD bispecifics behave in humans• Identification of anti-ErB2 dual variable domain
immunoglobulin proteins with unique activities• How are DvD bispecifics impacting disease in terms of
the pD markers?• What is the mechanism of action?Dr Tariq Ghayur, Senior Principal Scientist & Research Fellow, Abbvie
Bispecific Antibodies: strategies, considerations and challenges• Novel approaches to produce bispecific antibodies in a
single cell• Strategies to screen for bispecific antibodies • Designing bispecific antibodies to match the proposed
mechanism of action and intended clinical application Dr Christoph Spiess, Senior Scientist, Genentech
17:55
18:00
Chair’s closing remarks
Networking drinks reception
DAY 1 – MONDAY 9 NOVEMBER, 2015
See website for most up-to-date agenda
Save money and book early @ terrapinn.com/EAC2015
CMC and developability considerations
Dr Prathima Acharya, KBI Biopharma
Non-radioactive potency assays for ADCs
Dr Alexis Rossignol, R&D Project Manager, Clean Cells
A needle in a haystack. Shortcuts to
visualising and validating biomarkers for disease diagnosis and therapy
Jeremy Clarke & Richard Willock,
Asterand Bioscience
Analytics for ADCs
Alain Beck, Senior Director, Antibody
Physico-Chemistry, CIPF; Associate Editor, mAbsPartnering and licensing:
How to get your antibody to market quickly and cost-
effectively
Optimising drug delivery
Optimising GMP at a commercial scale
Tackling the challenges of Target Discovery
The next generation of antibody conjugates:
moving beyond cytotoxic payloads
Dr David Rabuka, Head of Global R&D, Chemical
Biology, Catalent
Using human tissue-based research solutions for antibody
drug discovery
How to use bioinformatics programmes for target discovery
Designing ADCs
Dr George Badescu, Scientific Director –
Conjugation & Protein Engineering, Abzena
ROUNDTABLES
To host a roundtable, speak to Jessicae/ [email protected]
DAY 1 – MONDAY 9 NOVEMBER, 2015
As there is so much competition in the antibodies sector it is now more important than ever that you keep up to date with the
latest developments and what competitors are working on. The European Antibody Congress
roundtable discussions do just this, they provide inside information that you can’t get anywhere else.
Take time to hear from leading providers and authorities in the antibody space and exchange knowledge and ideas with your peers in these
facilitated discussion sessions.
Confirmed roundtable discussions include:
08:00
09:00
09:15
09:40
10:05
Registration opens
Recap of Day 1 and opening remarks for Day 2
Recap of Day 1 and opening remarks for Day 2
Introduction from Chair
Early Discovery and Analytics
Computational biology
Computational biology in the discovery and development of antibodies
• Using new technology and collaboration to improve early development
• How can intracellular cascades increase precision of assays?
• Improvements in technology in discovery & development and how to use them
Dr Alexey Lugovskoy, Vice President, Therapeutics, Merrimack Pharmaceuticals
Antibody informatics for drug discovery
• Advancing specificity and safety for drug development
• Using antibody informatics to improve biophysical properties
• Predictive structural tools for biotherapeutics industry
Dr Bojana Popovic, Senior Scientist, Medimmune
Reserved for Supporting Partner
CMC/Developability
From Start to finish
Humabodies: ‘Right First Time’ - Human VH Fragments from a Transgenic Mouse
• Harnessing the natural process of B cell maturation to generate fully human VH fragments ready for development into clinical candidates
• Rapidly generating antibody fragments with improved developability attributes
• Target discovery for dermatology, oncology and ADCs for local action and decreased toxicity
Dr Thomas Sandal, VP of Preclinical Development and Protein Engineering, Crescendo Biologics
Developing a molecule which is stable/producible/has a high yield
• New methods in CMC and developability to create a successful biologic molecule
• How to form partnerships to get your antibody to manufacture and market quickly
• Streamlining your pipeline to develop and manufacture drugs more efficiently and easily
Representative from KBI Biopharma
Using serum compatibility and developability analyses to select bispecific antibodies
• How to increase developability of bispecifics using serum compatability
• Selection of bispecifics when considering later clinical stages
• What are the most important parameters to consider when selecting bispecific antibodies?
Dr Mark Chiu, Associate Director, Multispecific Biologics Engineering, Janssen
Platform Technology Showcase
A new targeted session exploring the most innovative new platform technologies being developed towards antibody engineering and development will take place.
Antibody drug developers will have the chance to see innovative pitches of new technologies that could help them get their pipeline to the next level.
See Page 17 for details
10:30 Networking refreshment break
DAY 2 – TUESDAY 10 NOVEMBER, 2015
11:40
12:00
12:40
12:20
Analytics
How new mass spectrometry methods are changing developability
• Using OptimAbs and OptimADCs platforms to speed up clinical development and increase therapeutic potential
• Identifying critical quality attributes (CQA) based on emerging analytical and structural methods
• Transforming antibodies and ADCs into drug candidates which are structurally optimised
Dr Alain Beck, Senior Director, Antibody Physico-Chemistry, Centre d’Immunologie Pierre Fabre; Associate Editor, mAbs
Practical considerations in manufacturability
• Assessing and selecting molecules with CMC development in mind
• Leveraging platform processes and methods to significantly increase speed to FIH
• Stage-appropriate investments in manufacturability
Dr Tanya Shang, Senior Principle Scientist, Analytical R&D, BioTherapeutics Pharmaceutical Sciences, Pfizer
Rosetta, a new programme for antibody analytics
• Using Rosetta for protein design. methods in making a new protein from scratch
• Targeting a specific receptor binding site to tackle influenza using proteomic software
• New methods in protein analytics and how they can be applied to biologic drug development
Dr Eva-Maria Straunch, Acting Instructor and Translational Investigator, Institute of Protein Design, Baker Lab, University of Washington
Improving product yield, stability, and binding capabilities for various construct design parameters
• Impacts of bispecific construct design variation on production and function
• Bispecific antibody facilitated targeting of the nanocells to cancer cells
• Fusion protein development for targeting in a non-cancer related indication cytokines for the treatment of type 2 diabetes
Dr Karin Taylor, Research Scientist, University of Queensland
Novel Constructs
Manufacture & purification
Old target — new mode of action: how to make extremely potent anti-ErbB2 agents
• Creating an intermolecular trap for ErbB2 to achieve pan-ErbB inhibition
• Eliciting apoptosis in ErbB2-addicted tumors
• Engineering novel cancer therapeutics with high tumoricidal activity while avoiding adaptive resistance and lowering side effects
Dr Rastislav Tamaskovic, Plückthun’s lab, Department of Biochemistry, University of Zurich
From a new analysis of IgG stability to mutants and formulations
• Best practice for checking complex molecules for mutations, lifespan and shelf life
• How to best apply kinetic analysis to predict the stability of molecules
• Assessing an effect of formulation on kinetic stability of antibodies
Dr Erik Sedlak, Associate Professor, Department of Biochemistry, P.J. Safarik University
Continuous production and purification of complex molecules
• ADC process development and scale-up strategy from early phase development to commercial
• How to ensure safe, effective and reliable manufacturing
• Tackling the main challenges of purifying ADCs
Dr Michel Eppink, Head of Downstream, Synthon
Are all recombinant proteins equal? A cell line development perspective
• Are there differences in the capability of a host cell line to express a ‘difficult to express’ protein?
• At what stage in the cell line development process is a first true read out of productivity and product characteristics possible?
• When can material be made available to feed other development stages?
Dr Alison Porter, Head of Mammalian Cell Culture R&D, Fujifilm Diosynth Biotechnologies
13:00 Networking lunch break
DAY 2 – TUESDAY 10 NOVEMBER, 2015
14:55
15:20
14:35 Target discovery
Using DNA Transposon technology for efficient mammalian-cell antibody library display
• A novel and highly efficient non-viral antibody discovery and engineering platform.
• Display of full-length antibodies on the surface B lymphocytes, i.e. their natural environment.
• Seamless integration of functional screening due to built-in switch between surface and secreted expression.
Dr Roger Beerli, CSO, NBE Therapeutics
Developing PD-L1 checkpoint antibodies using a novel discovery platform
• Generating high quality therapeutic antibody drug candidates quickly using a high-throughput approach incorporating human antibody libraries
• New methods in discovery and preclinical checkpoint antibody programs targeting multiple checkpoints
• Identifying development programs to be in a position to file investigational new drug applications
Dr Mark van Djik, Chief Technology Officer, 4-Antibody
Target discovery for the production of ADCs: new data from Genentech
• Novel target for AML
• Targeting stem cells in colon cancer
• Matching the linker-drug to the target and indication
Dr Andrew Polson, Senior Scientist, Genentech
Strategies in bioprocessing handling, analytical characterization & outsourcing
Reserved for supporting partner
Manufacturing & Platform Flexibility Through Continuous Chromatography Processing
• Using continuous processing techniques to lower the cost burden of disposable processing
• Integrating chromatography and filtration unit operations
• Simple, quick process development of continuous chromatography
• Applying a range of purification chemistries for platform variation
Dr Marc Bisschops, Principle Scientist, Continuous Processing & Rob Noel, Business Development Manager, Pall Life Sciences
A new paradigm and non-protein A platform for therapeutic IgG
• Five industry trends integrated in a new approach to IgG purification:
• Disposables, continuous processing, flow-through, without columns, without protein A
• All new data from case studies with a Blockbuster Biosimilar
Pete Gagnon, Project Director, Downstream Processing Group, Bioprocessing Technology Institute in Singapore
15:45 Networking refreshment break
16:30
17:10
16:50
Regulation & intellectual property
Latest European Patent Office guidelines and what they mean for mAbs, ADCs and multispecifics
Helena Domingues, Examiner, European Patent Office
POSTER SESSION
Informal, interactive presentation and discussion of diverse topics in the field of antibody discovery, development, manufacture and trials. Authors are invited to submit proposals relating to innovative projects, best practices and original research findings.
Refreshments will be served throughout
FDA Update: Antibody therapeutics focusing on ADCs, bispecifics and cancer immunotherapies
Dr Marjorie Shapiro, Chief, Laboratory of Molecular and Developmental Immunology, Division of Monoclonal Antibodies, CDER/FDA
DAY 2 – TUESDAY 10 NOVEMBER, 2015
17:50 Networking drinks reception
See website for most up-to-date agenda
Save money and book early @ terrapinn.com/EAC2015
Do you have a platform technology? You could be one of the 10 companies who will have the chance to pitch to a biotech and pharma audience.
Hear about the latest pioneering platform technologies: Sit in on the pitching session to what is out there and see if you could take your antibody development process to the next level.
Audience Participation: Give feedback, ask questions, make connections with innovators and perhaps form a new partnership.
See below for more details on how to get involved to get your technology in front of the right people.
Seeking partnership, investment, licencing or looking to sell your technology? Want to hear about the latest innovative platforms? Looking to invest?
Do you have a platform technology that you want to promote or sell? Are you looking for partnership, investment and licencing from big pharma and biotech companies?
If so, keep reading…
As part of the inaugural Platform Technology Showcase, we are offering you the opportunity to apply for one of ten 20 minute pitching slots available on Tuesday 10th November 2015. Each pitching slot consists of a 15 minute pitch and 5 minutes for questions from an audience of pharma, biotech and investors.
A new targeted session exploring the most innovative new platform technologies being developed towards antibody engineering and development will take place.
Antibody drug developers will have the chance to see innovative pitches of new technologies that could help them get their pipeline to the next level.
Ten 20 minute presentations showcasing innovative new platform technologies will take place alongside
the main scientific conference to a targeted room of professionals.
PLATFORM TECHNOLOGY SHOWCASE
To apply, speak to Derek ont/ +44 207 092 1297 e/ [email protected]
08:00
09:00
09:15
11:40
09:40
10:05
Registration opens
Recap of Day 2 and opening remarks for Day 3 Recap of Day 2 and opening remarks for Day 3
Preclinical development
Clinical development
Optimisation of immune-stimulating antibodies
• Preclinical development of immune stimulating antibodies with a view to later clinical stages
• Fc receptor interactions and antibody conformation direct distinct modes of activity
• Using in-vivo models to predict efficacy and toxicity
Dr Ann White, Senior Research Fellow, University of Southampton
Clinical development of AXL-ADC
• AXL as an ADC target
• Clinical candidate selection
• Activity of AXL-ADC in in vitro and in vivo models.
Dr Paul Parren, Senior Vice President and Scientific Director, Genmab
Producing better ADCs using ThioBridge™ conjugation
• From mouse antibody to human therapy
Dr George Badescu, Scientific Director – Conjugation & Protein Engineering, Abzena
Preclinical development of antibodies for transplantation, autoimmune and inflammatory diseases
• Looking at various formats of molecules to achieve specific properties
• Selecting molecules based on in vitro activity, in vivo stability and lack of immunogenicity
• Ensuring a preferable toxicology profile in preclinical development with clinical stages in mind
Dr Jiri Kovarik, Senior Research Investigator, Autoimmunity, Transplantation & Inflammation, Novartis Institutes for Biomedical Research (NIBR)
Future uses for antibodies
Inflammation and Neurology
Infectious Diseases
Broadly toxin-neutralizing and bactericidal antibodies to fight severe bacterial infections.
• Novel broad-spectrum Staphylococcus aureus toxin neutralizing antibodies
• Bactericidal mAbs to fight multi-drug resistant E. coli
• Choosing the right antibody discovery platform for individual targets
Dr Eszter Nagy, Co-Founder, President & CSO, Arsanis, Inc. Managing Director, Arsanis Biosciences GmbH
Targeting arthritic cartilage for immunotherapy and early diagnosis
• Developing a therapeutic to specifically target arthritic cartilage and specific and sensitive radiographic biomarkers for early diagnosis of OA
• Minimising side effects, damage to the rest of the body, increasing specificity
• Decreasing local dose and reducing cost of treatment
Dr Ahuva Nissim, Reader in Antibody and Therapeutic Engineering Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University
Development of DART® proteins for infectious disease applications
• Overview of DART platform and formats
• Activity of DARTs targeting HIV-infected cells for cytolysis
• Targeting Influenza and Dengue Virus by neutralization
Dr Syd Johnson, Vice President Antibody Engineering, Macrogenics
Antibodies and protection against invasive Salmonella disease
• Investigating the action of mechanism of antibodies with typhoidal and non-typhoidal Salmonella
• The relationship between protective epitopes and surrounding epitopes in Gram-negative bacteria
• The mechanisms through which antibody kills Gram-negative bacteria after vaccination
Prof Adam Cunningham, Professor of Functional Immunity, University of Birmingham
10:30 Networking refreshment break
DAY 3 – WEDNESDAY 11 NOVEMBER, 2015
12:00
12:20
12:40
Considering immunogenicity of IgGs and mAbs in ensuring clinical viability of therapeutics
• Evaluating clinically relevant immunogenicity
• Optimising treatments with respect to how much you dose
• How to manage the use of these biologicals in clinic Dr Theo Rispens, Group Leader, Department of Immunopathology Research, Sanquin Research
Transforming antibody development via innovative partnering
• How can partnerships between academia and industry improve drug development?
• Using novel business models to progress the drug pipeline and resurrect deprioritised candidates
• Working with Medimmune in development and discovery; an update
Dr Robert Williams, Chief Development Scientist, Drug Development Office, Cancer Research UK
How to decrease costs in trials
• Scaling up, addressing the challengesReserved for supporting partner
Reserved for supporting partner
Developing targeted CNS biotherapeutics and approaching difficult membrane-associated targets
• Utilizing the VNAR scaffold to engineer differentiated products in a variety of formats including monospecific and bispecifics
Dr Frank Walsh, CEO, Ossianix
Brain shuttle platform to open the blood brain barrier gate for biologics
• Blood brain barrier the challenges for CNS drug delivery
• Brain delivery of biotherapeutics
• The pRED Roche Brain Shuttle PlatformDr Per-Ola Freskgard, Vice Director and Expert Scientist Neuroscience, Roche Innovation Center Basel Switzerland
13:00 Networking lunch break
14:35
The future of antibodies
Antibodies to watch out for in 2016• Record numbers of recombinant antibody products received first marketing approvals in 2014 and 2015.
Products that might be granted approvals in 2016 will be identified and discussed. • Phase 3 clinical study results for a record number of antibody therapeutics are due in 2015. Study results
will be compared and contrasted, and the question of which antibodies are likely to move to regulatory review will be explored.
• So far, few ‘next generation’ formats such as antibody-drug conjugates and multi-specific antibodies have progressed to late-stage clinical studies. The current commercial pipeline of these promising formats will be assessed.
Dr Janice Reichardt, Editor in Chief, mAbs
15:00
15:30
Thank you & closing remarks by Terrapinn
END OF CONGRESS
See website for most up-to-date agenda
Save money and book early @ terrapinn.com/EAC2015
DAY 3 – WEDNESDAY 11 NOVEMBER, 2015
GOOD. DIVERSE SELECTION OF PRESENTATIONS INCLUDING TALKS WITH NEW INFORMATION WHICH IS IMPORTANT.”
“
SVP & CSO AMPLIMMUNE
IT’S A NETWORKING EVENTThe European Antibody Congress recognizes the importance of networking and offers an experience which allows you to do just that.
ROUNDTABLE DISCUSSIONS
With moderators to lead discussions on key topics, you will take your engagement and learnings to a new level in this interactive and results-driven setting.
NETWORKING RECEPTION
It’s not always about the conference sessions. Our themed evening networking drinks receptions both at the conference venue and off-site
on days one and two will allow you to unwind with your peers and continue conversations in good company.
NETWORKING LUNCHES
Our extended lunch periods will provide you with ample time to network between sessions. These lunch formats allow for more
opportunities for casual conversations and introductions, without compromising your time attending the conference sessions.
SCIENTIFIC POSTERS
Share research with leaders in the antibody sector within the dedicated Scientific Poster session. Posters allow for pharma, biotech and academia to present previously unpublished work. Taking place before the networking drinks on day two of the congress, it will be possible for poster contributors to answer questions and gain feedback. Refreshments will be served throughout.
Please see terrapinn.com/EAC2015 for further details.
‘Good. Diverse selection of presentations including talks with NEW information which is important.’ SVP & CSO, AMPLIMMUNE
‘High scientific value of the talks, knowledgeable speakers, great networking with European entities, especially for US based companies’ VP, AMBRX INC.
‘Very useful overview of many biotech players’ pipelines and projects. Easy to reach, well organized.’ SENIOR SCIENTIFIC ADVISOR, EFFIMUNE
‘Excellent new research in the area of Antibody Engineering. Very innovative. Excellent list of speakers. Beautifully organized meeting’ CSO, BIOMUNEX PHARMACEUTICALS
‘The best global Antibody meeting’ SENIOR DIRECTOR, CIPF
‘Really good list of speakers and very topical sessions; I also enjoyed the size of the meeting (not huge), which allowed for making new connections.’SENIOR SCIENTIST, ANTIBODY DISCOVERY, JOUNCE THERAPEUTICS
WHAT OUR CUSTOMERS SAY
WHO ATTENDSSenior Principal Scientist and Research Fellow, AbbVie Bioresearch Center Inc Managing Director, AbCheck R&D Team Leader, AbD Serotec Scientific Director – Conjugation and Protein Engineering, Abzena Chief Executive Officer, Advanced BioDesign Deputy General Manager, Ajinomoto Co Inc Managing Director, Aldevron CSO, Ambrx Scientific Director, Amgen Research Munich Spa Senior Vice President R&D and CSO, Amplimmune Vice President of Antibody Engineering, Macrogenics Chief Development Officer, arGEN-X Principal Scientist, Asterand Bioscience Senior Director of Business Development, Asterand U.K. Vice-president, Atlanpole Biotherapies Project Manager, Atlanpole Biotherapies Bioprocessing Applications & Scientific Manager, BD Biosciences - Advanced Bioprocessing Patent Counsel, Bemido SA Senior Scientist, Clinical
Research, Biogen Idec Chief Scientific Officer, BIOMUNEX PHARMACEUTICALS Managing Director, BioPortfolio Lab Head of N.B.E. Discovery, Boehringer Ingelheim Pharma GmbH & Co. KG Senior Vice President of Immuno-Oncology & Biologics Discovery, Bristol Myers Squibb Vice President of C.M.C, C.M.C. Ambrx Inc Director of N.P.O. Sourcing and Operations, Cannondale Securities Llc Head of Research and Development, Catalent Pharma Solutions Chief of Laboratory of Molecular and Developmental Immunology, CDER, FDA Director, Molecular and Cellular Biology, Centre d’Immunologie Pierre Fabre Senior Director, Antibody Physico-Chemistry, Centre d’Immunologie Pierre Fabre Head of Experimental Cancer Research Department, Centre D’Immunologie Pierre Fabre Principal Scientist, Chemical Computing Group CEO, ChemPartner Director Biologics, ChemPartner Executive Director, ChemPartner R&D Project Leader, Cisbio Bioassays Research and Development Project Manager, Clean Cells Group Leader & Lab Manager, Target Discovery, Compugen Ltd Director, Process Development, Cook Pharmica CEO Managing Partner, Creoptix AG CTO, Managing Partner, Creoptix AG VP of Preclinical Development and Protein Engineering, Crescendo Biologics Ltd Chief Scientific Officer, Crystal Bioscience Director of Cell Biology, CytomX Therapeutics, Inc CSO, CytomX Therapeutics, Inc Chief Scientific Officer, Debiopharm International Sa Deputy Director General, Development Center for Biotechnology Senior Scientific Advisor, Effimune Head Of In Vitro Preclinical Development, ElsaLys Biotech Director, emdmillipore Associate Professor, ETH Zurich Patent Examiner European Patent Office, European Patent Office Examiner, Joint Cluster Biotechnology, Immunology Directorate, European Patent Office Senior Scientist, Fraunhofer Gesellschaft Principal Scientist, Fujifilm Diosynth Biotechnologies Vice President R and D, GamaMabs Senior Scientist, Genentech Senior Director and Staff Scientist, Antibody Engineering, Genentech Senior Vice President and Scientific Director, Genmab Director Antibody Therapeutics Genomics, Institute of the Novartis Research Foundation CSO, Genovis AB Founder, Chief Executive Officer and Chief Scientific Officer, Glycotope GmbH Director Science and Technology, GSK Directeur Général, Gustave Roussy Comprehensive Cancer Center General Manager, Histalim Director, Ibc Generium/CellThera Pharm Chief Technology Officer, Icosagen Cell Factory OU Manager of Business Development, Immatics Biotechnologies Gmbh Chief Scientific Officer, Immunocore Executive Vice President & Distinguished Research Fellow, ImmunoGen Director Antibody Platform, Innate Pharma Director of Pharmaceutical Operations, Innate Pharma Professeur des Universités Praticien Hospitalie, Inserm Chief Executive, Investigación Aplicada, S.A de C.V Managing Director, Pharmalicensing & VP, Technology Marketplaces, Iptechex Pharmalicensing Chief Scientific Officer, Isogenica Ltd Director Of Preclinical Operations, ITALFARMACO S.P.A. Head of Biologics Research, Biotechnology COE, Janssen Senior Director of Antibody Drug Discovery, Janssen Associate Director, Multispecific Biologics Engineering, Janssen Research and Development Llc Senior Scientist, Antibody Discovery, Jounce Therapeutics, Inc. Chief Scientific Officer and Head of Business Development, K.B.I. Biopharma Drug Metabolism and Pharmacokineties, LFB Biotechnologies Chief Executive Officer, M.A.B. Discovery Gmbh Editor-in-Chief, mAbs Landes Bioscience Principal, Maschio & Soames IP Limited Operations Director, Maschio & Soames IP Limited Director, Maschio and Soames IP Senior Scientist, Oncology Research, MedImmune Senior Director of Research and Development, MedImmune Director of Oncology Research, MedImmune Business Scout, Menarini Biotech S.R.L. Principal Scientist, Bioprocess Development, Merck Business Developer Emerging Biotech Market, Merck Group Gmbh Director of Technical Development Biosimilars, Merck Serono Senior Director, Nanotherapeutics, Merrimack Pharmaceuticals Vice President of Therapeutic Design, Merrimack Pharmaceuticals Senior Scientist, Merus BV. Antibody Group Manager, MI-mAbs / Aix Marseille Université Founder and Chief Executive Officer, ModiQuest Research Expert Scientist, Molecular Partners AG Senior Consultant, N.D.A. Regulatory Science Ltd Associate Investigator, National Institute of Cancer Research Distinguished Investigator and Attending Physician, National Institute of Cancer Research, National Health Research Institutes Genomics & Biomedical Data Lead, NHS England Global Head Developability Assessment, Integrated Biologics Profiling, Novartis Head of Molecular Interaction Facility, NovImmune Sa CBO & Co-Chief Executive Officer, Numab AG CSO and Co-CEO, Numab Ag Vice President Marketing Biopharmaceuticals Europe, Pall Life Sciences Director, Protein Discovery and Optimisation Group, Pfizer Vice President, Pfizer Worldwide Research and Development. Senior Principal Scientist, Pfizer, Inc Chief Executive Officer, Pharmatching Director, PharmaVision Vice President Early Discovery, Pieris Ag Scientific Director R&D, Quality Assistance Managing Director, Retrogenix Biomarker Experimental Medicine Leader, Senior Principal Scientist, Roche Senior Translational Medicine Leader, Roche Scientific Director, Roche Managing Director, European Operations, SafeBridge Europe D.S.P. Laboratory Manager, SANOFI Project Manager of Custom Synthesis, Sanofi Aventis Research and Development Scientific Affairs & Strategics Support, Sanofi Global Biotherapeutics Head of Product Development, Solvinax Vice President of Research, Sutro Biopharma Director of Chemistry, Sutro Biopharma Vice President of Research, Sutro Biopharma Chief Operating Officer, Swiss Biotech Association Co-founder, Philogen Senior Scientist, Symphogen A/S Managing Director, The Chemistry Research Solution Project Manager, Tillotts Pharma AG Director, Antibody Discovery, U.C.B. Associate Professor, Department of Internal Medicine, University Hospital of Wuerzburg CSO, SpectraMab Assistant Professor, Section for Stem Cell Transplantation and Immunotherapy, University Of Kiel Professor of Immunochemistry, University of Southampton Chief Scientific Officer, Viventia Bio Inc. Director of Research, Viventia Biotechnology Inc Senior Director, Wuxi App Tec Senior Research Director, Xencor, Inc. Chief Technology Officer, Zymeworks
Over 400 delegates will be attending this year from pharma, biotech, clinicians, academics, researchers and start-ups
Here is a sample delegate list of those who attended last year:
THE EXHIBITIONConference Rooms
Breakout Rooms
317
21 22 2425
26
23
18 19 20
271
416 15
14
13
12
11
10 28
33 34 35 36 37 43
42 45
41 46
44
3231
38 39 40
30299
5
6
7
8
2
2,00
2,00
3,00
3,00
2,00
2,00
2,00
2,00
2,00
2,00
2,00
2,00
2,00 2,00
2,00
3,00
4,00
3,00
3,00
3,00
4,00
4,00
4,003,00
3,00
4,00
3,00
6,00
4,00
3,00
3,00
3,00
3,00
3,00
3,00
4,003,00
3,00 3,00 3,00 3,00
3,00 3,004,00 6,00
6,00 6,00 4,00
4,00
4,00
4,00
6,00
3,00
3,00 3,00 3,00
3,00 3,00
3,00
3,00
3,00
3,00
3,00
3,00
3,00
3,00
3,00
3,00
AVAILABLE
RESERVED
SOLD
• Pharmaceutical manufacturers• API/HPAPI manufacturers• Handling and containment services• Safety services• Bioprocessing services and equipment• CMOs
• Platform technology• CROs• CMOs• Turnkey equipment providers• Bioprocessing services and equipment• Bio-informatics and computational biology
• Market access consultants• Regulatory consultants• Comparative analytics• Platform technology• CMOs• Sourcing services
WHO EXHIBITS?
CONFIRMED 2015 EXHIBITORSWHY EXHIBIT?• Generate new business leads
• Build brand presence and awareness
• Forge strategic partnerships and joint ventures
• Showcase latest products
• Promote new services to prequalified clientele
GET INVOLVED• Book a stand
• Join our digital marketing campaign
• Take part in pre-event networking
• Help shape the event plans
• Invite your clients
• Book prospective meetings onsite
COMPANY COMPANY COMPANYSTAND NO. STAND NO. STAND NO.
Asterand Pall Catalent1 13 34
7 15 35
8 17 36
10 19 37
11 20 42
12 33 43
LFB Biomanufacturing Clean Cells Myoderm
Sycomore Aldevron Genovis
Agilent DrugDesigntech Maschio and Soames
KBI FPS Pharma & Food Systems Quality Assistance
Fujifilm Diosynth Horiba Abd Serotec a Bio Rad Company
Updated 8 May
Can’t find a package that’s right for you? Talk to Derek about tailoring something to meet your exact needs.Derek Cavanagh t/ +44 207 092 1297 e/ [email protected]
SPONSORSHIP ANDEXHIBITION PACKAGES
BENEFITS
Keynote Plenary Presentation or Interview
Access to Networking Manager
Roundtable Host
Delegate passes
Track Presentation
Lead generation services
On-Floor Demonstration
Exhibition booth
Platform tech pitch
PLATINUM
1
Up to 12 meetings
2
6
1
2 emails
2
24 sqm
SILVER
Up to 5 meetings
1
2
Newsletter
1
9 sqm
GOLD
Up to 8 meetings
1
3
1
1 email
1
12 sqm
EXHIBITION
Added on request
Purchased by sqm – 6 up to 24
PLATFORM TECH PACKAGE
1
1
REGISTER YOUR PLACE TODAY
The earlier you book the more you’ll save.
For the latest price see terrapinn.com/EAC2015
BRING YOUR TEAM
With three days packed full of great content and networking opportunities, you can't possibly cover it all alone!
Bring your team and get an extra discount.
Call +44 (0) 207 092 1210
BOOK NOW
Register atterrapinn.com/EAC2015
Or call +44 (0) 207 092 1210
Package
Delegate Booking
Standard Package
Academic Package
Poster
£1620 SAVE £1348
£815 SAVE £669
£50
£2430 SAVE £540
£1215 SAVE £270
£50
£2160 SAVE £810
£1080 SAVE £405
£50
£2565 SAVE £405
£2835 SAVE £135
£1285 SAVE £200
£1415 SAVE £70
£50 £50
£2700 SAVE £270
£2,970
£1350 SAVE £135
£2,015
£50 £50
Before 29-May-15
Before 21-Aug-15
Before 12-Jun-15
Before 11-Sep-15
Before 23-Oct-15
Before 02-Oct-15
Final Price
SPONSORS EXHIBITORS
For sponsorship and exhibition opportunities, please contact Derek Cavanagh t/ +44 (0) 207 092 1297 e/ [email protected] terrapinn.com/EAC2015
Event Partners
Media Partners
Exhibitors
Sponsors
